Symphogen is a leading clinical stage antibody oncology-focused company with a differentiated monoclonal antibody, or mAb, mixture product pipeline with significant clinical potential and commercial opportunities. Our vision is to develop superior mAb therapeutics to improve the lives of patients with significant unmet medical needs. Our novel biologic approach is uniquely designed to address tumor diversity and resistance by combining multiple antibodies in a single drug product. The proprietary pipeline of three unencumbered clinical stage oncology programs addresses clinically validated targets, is supported by strong preclinical data, has broad intellectual property protection, and addresses today's need for precision medicine. The application of the mAb platform outside cancer is currently pursued through strategic partnerships.

Key elements of our strategy:

  • Advance the clinical development of our proprietary pipeline of mAb mixture product candidates towards regulatory approval
  • Continue to leverage and invest in our mAb mixture platform to discover and develop additional product candidates, including in the fields of immuno-oncology and other disease areas
  • Develop precision medicine products by focusing on potential therapies for subgroups of patients with significant unmet medical needs, including where expedited regulatory pathways may be available
  • Continue to selectively pursue collaborations and other partnering opportunities with leading pharmaceutical companies


Symphogen is primarily funded by international healthcare focused investors, and the company has raised a total of €317 million to date in equity capital. Current key shareholders include:

Essex Woodlands Health Ventures
Novo Holdings A/S
Sunstone Capital
Gilde Healthcare Partners
Danica Pension
Takeda Ventures, Inc.